EGFR and neoplasm: Rather than global overexpression of EGFR throughout the tumour, our data in the J3T cell line shows that a minority population of CSCs do not over-express of EGFR but do have constitutive activation of EGFR compared to the bulk of the tumour cells, that can be attenuated by treatment with gefitinib.